Korean J Urol.  2012 Dec;53(12):821-825. 10.4111/kju.2012.53.12.821.

Efficacy and Safety of Hexaminolevulinate Fluorescence Cystoscopy in the Diagnosis of Bladder Cancer

• Lee JS
• Lee SY
• Kim WJ
• Seo SI
• Jeon SS
• Lee HM
• Choi HY
• Jeong BC

• KMID: 1988725
• DOI: http://doi.org/10.4111/kju.2012.53.12.821

Abstract

PURPOSE
The aim of this study was to evaluate the efficacy and safety of hexaminolevulinate fluorescence cystoscopy in the diagnosis of bladder cancer.
MATERIALS AND METHODS
In a prospective design, we included patients who had a bladder lesion suggesting bladder cancer. Patients with massive hematuria, urethral Foley catheter insertion, chronic retention state, or urinary tract infection were excluded. After the bladder was emptied, hexaminolevulinate was gently administered into the bladder. One hour later, cystoscopy under white light and blue light was performed. After marking the lesions confirmed with white light or blue light, transurethral resection of the bladder lesion and pathologic confirmation were done. Transurethral resection of the lesions that were negative in both white and blue light was also performed.
RESULTS
From April 2010 to September 2010, 30 patients were enrolled. From the total of 30 patients (25 men and 5 women; mean age, 60.4+/-9.22 years), 134 specimens were extracted. Among these, 101 specimens showed positive results by blue light cystoscopy (BLC). The sensitivity of BLC and white light cystoscopy (WLC) was 92.3% and 80.8%, respectively (p=0.021). The specificity of BLC and WLC was 48% and 49.1%, respectively (p>0.05). The positive and negative predictive values of BLC were 71.2% and 81.8%, respectively, whereas those of WLC were 72.0% and 68.6%, respectively. With WLC, 48 specimens showed negative findings, but of that group, 15 specimens (31.2%) were revealed to be malignant with BLC. There were no significant side effects in the 24 hours after the instillation of hexaminolevulinate.
CONCLUSIONS
Photodynamic diagnosis with hexaminolevulinate helps to find tumors that could be missed by use of WLC only. Photodynamic diagnosis might be valuable in complete resection as well as for more accurate diagnosis of bladder tumor.

Keyword

Bladder cancer; Diagnostic imaging; Hemainolevulinate

MeSH Terms

Aminolevulinic Acid
Catheters
Cystoscopy
Diagnostic Imaging
Fluorescence
Hematuria
Humans
Light
Male
Prospective Studies
Retention (Psychology)
Sensitivity and Specificity
Urinary Bladder
Urinary Bladder Neoplasms
Urinary Tract Infections
Aminolevulinic Acid

Reference

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007; 18:581–592. PMID: 17287242.

2. Holmang S, Hedelin H, Anderstrom C, Holmberg E, Johansson SL. Prospective registration of all patients in a geographical region with newly diagnosed bladder carcinomas during a two-year period. Scand J Urol Nephrol. 2000; 34:95–101. PMID: 10903069.

3. Brausi M, Collette L, Kurth K, van der Meijden AP, Oosterlinck W, Witjes JA, et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol. 2002; 41:523–531. PMID: 12074794.

4. Witjes JW, Kiemeney LA, Verbeek AL, Heijbroek RP, Debruyne EM. the members of the Dutch South East Cooperative Urological Group. Random bladder biopsies and the risk of recurrent superficial bladder cancer: a prospective study in 1026 patients. World J Urol. 1992; 10:231–234.

5. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006; 49:466–477. PMID: 16442208.

6. Denzinger S, Burger M, Walter B, Knuechel R, Roessler W, Wieland WF, et al. Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study. Urology. 2007; 69:675–679. PMID: 17445650.

7. Jakse G, Algaba F, Malmstrom PU, Oosterlinck W. A second-look TUR in T1 transitional cell carcinoma: why? Eur Urol. 2004; 45:539–546. PMID: 15082193.

8. Jichlinski P, Leisinger HJ. Fluorescence cystoscopy in the management of bladder cancer: a help for the urologist. Urol Int. 2005; 74:97–101. PMID: 15756058.

9. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol. 2011; 59:997–1008. PMID: 21458150.

10. Jocham D, Stepp H, Waidelich R. Photodynamic diagnosis in urology: state-of-the-art. Eur Urol. 2008; 53:1138–1148. PMID: 18096307.

11. Witjes JA, Moonen PM, van der Heijden AG. Comparison of hexaminolevulinate based flexible and rigid fluorescence cystoscopy with rigid white light cystoscopy in bladder cancer: results of a prospective Phase II study. Eur Urol. 2005; 47:319–322. PMID: 15716194.

12. Jocham D, Witjes F, Wagner S, Zeylemaker B, van Moorselaar J, Grimm MO, et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol. 2005; 174:862–866. PMID: 16093971.

13. Kriegmair M, Baumgartner R, Knuchel R, Stepp H, Hofstadter F, Hofstetter A. Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence. J Urol. 1996; 155:105–109. PMID: 7490803.

14. Filbeck T, Roessler W, Knuechel R, Straub M, Kiel HJ, Wieland WF. Clinical results of the transurethreal resection and evaluation of superficial bladder carcinomas by means of fluorescence diagnosis after intravesical instillation of 5-aminolevulinic acid. J Endourol. 1999; 13:117–121. PMID: 10213106.

15. Daniltchenko DI, Riedl CR, Sachs MD, Koenig F, Daha KL, Pflueger H, et al. Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. J Urol. 2005; 174:2129–2133. PMID: 16280742.

16. Lange N, Jichlinski P, Zellweger M, Forrer M, Marti A, Guillou L, et al. Photodetection of early human bladder cancer based on the fluorescence of 5-aminolaevulinic acid hexylester-induced protoporphyrin IX: a pilot study. Br J Cancer. 1999; 80:185–193. PMID: 10389995.

17. Schmidbauer J, Witjes F, Schmeller N, Donat R, Susani M, Marberger M, et al. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol. 2004; 171:135–138. PMID: 14665861.

18. Jichlinski P, Guillou L, Karlsen SJ, Malmstrom PU, Jocham D, Brennhovd B, et al. Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer: a multicenter study. J Urol. 2003; 170:226–229. PMID: 12796694.

19. Geavlete B, Mulţescu R, Georgescu D, Jecu M, Geavlete P. HAL fluorescence cystoscopy and TURB one year of Romanian experience. J Med Life. 2009; 2:185–190. PMID: 20108538.